Melatonin receptor agonist neu-pll improves insulin resistance in T2DM rats
10.3969/j.issn.1001-1978.2020.02.014
- Author:
Ying-Chun GAO
1
Author Information
1. 940fA Hospital of Joinl Logistics Support Force of Pla
- Publication Type:Journal Article
- Keywords:
Melatonin;
Mfn2;
Neu-pll;
Nrf-1/2;
Pgc-la;
Sirtl;
Type 2 diabetes
- From:
Chinese Pharmacological Bulletin
2020;36(2):221-225
- CountryChina
- Language:Chinese
-
Abstract:
Aim To study the effect of melatonin receptor agonist Neu-pl 1 on IR in T2DM rats and to predict its possible mechanism. Methods Long-term high-fat feeding plus low-dose streptozotocin (STZ, 30 mg • kg"1, IP) were used to induce an animal model of type 2 diabetes in female rats. After 4 weeks of intragastric administration, liver tissue was sacrificed. Hie mRNA expression levels of Sirtl, Nrf-1/2 and ERRa in rats were determined by RT-PCR. The relative expressions of PGC-la and Mfn2 were determined by Western blot. Rat INS was measured and HOME-IR and ISI were calculated. The liver ATP content and ATPase activity were measured. Results Compared with normal group, T2DM rats developed IR, PGC-la, Mfn2 protein expression increased, Sirtl and other mRNA expression decreased significantly, ERRa mRNA expression increased, ATP content decreased significantly, and ATPase activity decreased. Compared with model group, the Neu-pll low-dose group reduced INS in T2DM rats, improved IR in T2DM rats, up-regulated rat liver protein and mRNA expression, down-regulated ERRa mRNA expression, and increased rat liver ATP content and ATPase activity. Conclusions The melatonin receptor agonist Neu-pl 1 may improve IR by regulating the mitochondrial bal-ance-related factors in liver of T2DM rats and maintaining normal mitochondrial function.
